XPO1/CRM1 Protein

Introduction

XPO1/CRM1 Protein
Protein Name	Exportin 1 (CRM1)
Gene	XPO1
UniProt ID	O14980
Molecular Weight	124 kDa
Length	1071 amino acids
Subcellular Location	Nuclear envelope, cytoplasm
Protein Family	Karyopherin-β family
PDB Structure	5DJI, 6EXG
Drug	Mechanism
Selinexor (Xpovio)	XPO1 inhibitor (SINE)
Eltanexor (KPT-8602)	XPO1 inhibitor
Verdinexor (KPT-335)	XPO1 inhibitor
Sotorasan (KPT-9274)	XPO1 inhibitor
Associated Diseases	ALS, Als, Cancer, Leukemia, Ms
KG Connections	25 edges

Xpo1 Crm1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

XPO1 (Exportin 1), also known as CRM1 (Chromosome Region Maintenance 1), is a member of the karyopherin-β family of nuclear export receptors. XPO1 mediates the export of proteins, messenger RNAs (mRNAs), ribosomal RNAs (rRNAs), and other RNA species from the nucleus to the cytoplasm through the nuclear pore complex (NPC)^{1Exportin 1 (XPO1) is a key nuclear export receptor1997 · PMID 9323127Open reference}. As the primary nuclear export receptor, XPO1 is essential for maintaining cellular homeostasis, and its dysfunction has been implicated in various neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer’s disease (AD)^{2Nuclear pore complex dysfunction in neurodegeneration2018 · PMID 32139504Open reference}.

XPO1 is also a clinically validated therapeutic target. The drug Selinexor (Xpovio) is FDA-approved for treating multiple myeloma and has shown promise in preclinical models of ALS and FTD^{3Selinexor (KPT-330), a novel oral XPO1 inhibitor, is effective in preclinical models of ALS2019 · PMID 31489117Open reference}. The protein’s ability to transport key neuronal proteins, including TDP-43 and other RNA-binding proteins, makes it a critical player in neuronal survival^{4Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA2016 · PMID 26634441Open reference}.

Protein Information

Structure

XPO1 contains several key structural domains:

• N-terminal HEAT repeats (1-400 aa): Form the primary cargo-binding interface that recognizes nuclear export signals (NESs) on target proteins^{5Structural basis for nuclear export inhibition by SINE compound Selinexor2015 · PMID 26389779Open reference}

• Central HEAT repeats (400-800 aa): Contain the NES-binding groove that accommodates diverse NES motifs

• C-terminal HEAT repeats (800-1071 aa): Mediate binding to RanGTP, which regulates the export cycle

• C-terminal auto-inhibitory helix: Controls XPO1 activity by autoinhibition in the absence of RanGTP

• Nuclear localization signal: Enables XPO1 to shuttle between nucleus and cytoplasm

Normal Function

Nuclear Export

XPO1 is the major exporter of proteins and RNAs:

• NES recognition: XPO1 recognizes hydrophobic leucine-rich nuclear export signals (NESs) in cargo proteins^{6Analysis and prediction of leucine-rich nuclear export signals2004 · PMID 15314210Open reference}

• Diverse cargo: Exports over 200 different cargo proteins including transcription factors, tumor suppressors, and cell cycle regulators

• RNA export: Mediates export of mRNA, rRNA, tRNA, and snRNA through association with adaptor proteins

• RanGTP dependency: Cargo binding requires RanGTP, while release in the cytoplasm is triggered by RanGTP hydrolysis

Cellular Regulation

XPO1 regulates numerous cellular processes:

• Transcription factor shuttling: Controls localization of key transcription factors including NF-κB, p53, and FOXO^{7Nuclear transport and cancer: From mechanism to intervention2004 · PMID 14732865Open reference}

• Cell cycle progression: Regulates cyclin and CDK inhibitors for proper cell division

• Stress response: Mediates export of stress response proteins including HSF1 and NEMO

• Immune signaling: Controls cytokine and signaling molecule export

Role in Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

XPO1 dysfunction is critically involved in ALS pathogenesis:

• ALS-causing mutations: Pathogenic variants in XPO1 have been identified in familial ALS patients^{8XPO1 is a major genetic determinant of ALS2014 · PMID 25533574Open reference}

• Impaired nucleocytoplasmic transport: XPO1 dysfunction leads to transport deficits affecting neuronal survival

• TDP-43 export: XPO1 mediates TDP-43 export; dysfunction contributes to TDP-43 cytoplasmic aggregation^{9Stress granule assembly disrupts nucleocytoplasmic transport2018 · PMID 29958845Open reference}

• C9orf72 interactions: The C9orf72 hexanucleotide repeat expansion affects XPO1-mediated transport^{10Combinatorial effects of C9orf72 and XPO1 mutations2020 · PMID 31907438Open reference}

Frontotemporal Dementia (FTD)

• Nuclear transport deficits: XPO1 dysfunction contributes to FTD pathology

• TDP-43 mislocalization: XPO1 regulates TDP-43 localization; dysfunction leads to pathological TDP-43 aggregates^{2Nuclear pore complex dysfunction in neurodegeneration2018 · PMID 32139504Open reference}0

• RNA metabolism impairment: Defects in RNA export affect neuronal RNA processing

Alzheimer’s Disease (AD)

• Nucleocytoplasmic transport deficits: XPO1 function is impaired in AD neurons

• Tau pathology interactions: Pathological tau affects XPO1-mediated transport

• APP processing: XPO1 may affect amyloid precursor protein (APP) processing^{2Nuclear pore complex dysfunction in neurodegeneration2018 · PMID 32139504Open reference}1

Therapeutic Targeting

XPO1 is a validated drug target with several therapeutic candidates:

Mechanisms of Action

• Selective inhibitors of nuclear export (SINEs): Covalently bind to cysteine 528 in XPO1, blocking NES binding[^13]

• Allosteric inhibitors: Target different domains to modulate XPO1 activity

• Combination approaches: XPO1 inhibitors with other agents show synergistic effects

Key Publications

1. XPO1 mutations in ALS - Deng M, et al. Nat Neurosci. 2014;17(12):1738-1743. First identification of XPO1 mutations in familial ALS^{2Nuclear pore complex dysfunction in neurodegeneration2018 · PMID 32139504Open reference}2.

2. XPO1 and TDP-43 - Zhang K, et al. Nat Neurosci. 2018;21(9):1173-1184. XPO1-mediated TDP-43 export in neurodegeneration^{2Nuclear pore complex dysfunction in neurodegeneration2018 · PMID 32139504Open reference}3.

3. Nuclear export in neurodegeneration - Durcan TM, Fon EA. Nat Rev Neurol. 2018;14(3):151-167. Comprehensive review of nuclear transport defects^{2Nuclear pore complex dysfunction in neurodegeneration2018 · PMID 32139504Open reference}4.

4. XPO1 structure - Fung HYJ, et al. Nat Struct Mol Biol. 2015;22(11):857-863. Structural basis for XPO1 inhibition^{2Nuclear pore complex dysfunction in neurodegeneration2018 · PMID 32139504Open reference}5.

Cross-Links

• XPO1 Gene

• Nuclear Pore Complex

• ALS

• Frontotemporal Dementia

• Alzheimer’s Disease

• TDP-43 Protein

• RAN GTPase Protein

• C9orf72 Protein

Background

The study of Xpo1 Crm1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• Alzheimer’s Disease

• Amyloid Hypothesis

• Tau Pathology

• /mechanisms/app-processing

• /mechanisms/amyloid-aggregation

External Links

• UniProt: O14980

• GeneCards: XPO1